September 28, 2026

To The Manager, Listing Department **National Stock Exchange of India Ltd.** Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: **BLISSGVS**	To The General Manager, Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: **506197**

Dear Sir/Madam,

Subject: Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Ref: Disclosure under Regulations 30 of the SEBI Listing Obligations.

Pursuant to Regulations 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 **(“SEBI Listing Regulations”)**, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. September 28, 2026, has, inter alia, considered and approved/noted the following matters in relation to the consummation of the transaction contemplated in the share purchase agreement dated May 23, 2026 (“**SPA**”) entered into amongst Anupam Rasayan India Limited (“**Purchaser**”), the Sellers (as defined in the SPA), including Mr. S. N. Kamath as Seller 1 (as defined in the SPA), read with the Deed of Adherence dated July 17, 2026 executed between Mates Visa Consultancy Private Limited (“**PAC**”) and the Purchaser whereby the Purchaser had assigned its rights under the SPA to PAC (collectively, “**Transaction Documents**”):

1) Change in Control and Promoter Status:

The PAC has completed the acquisition of 5,09,84,595 equity shares of Bliss GVS Pharma Limited (“**Company**”), representing 47.95% of the equity share capital of the Company as on date of the meeting, pursuant to the consummation of the transaction contemplated in the SPA on September 28, 2026. Following the aforesaid acquisition, and together with 1669 equity shares of the Company acquired by the Purchaser under the Open Offer, the Purchaser and the PAC collectively hold an aggregate of 5,09,86,264 equity shares of the Company, representing 47.95% of the equity share capital of the Company.

Accordingly, with effect from September 28, 2026, Anupam Rasayan India Limited, along with Mates Visa Consultancy Private Limited, being the Purchaser and PAC, respectively, have acquired control of the Company pursuant to the completion of the Open Offer (as defined in the SPA) and the consummation of the transaction contemplated under the SPA and therefore have become the **‘Promoters’** of the Company in accordance with the applicable provisions of the SEBI Listing Regulations and the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

2) **Appointment of Directors**:

a) Appointment of Mr. Hetul Krishnakant Mehta [DIN:01650314] as an Additional Director of the Company in the capacity of a Non-Executive Non-Independent Director with effect from September 28, 2026.

b) Appointment of Mr. Amar Dilip Shah [DIN: 00214357] as an Additional Director of the Company in the capacity of a Non-Executive Non-Independent Director with effect from September 28, 2026.

c) Appointment of Mr. Pramod Badrinarayan Kasat [DIN: 00819790] as an Additional Director of the Company in the capacity of a Non-Executive Non-Independent Director with effect from September 28, 2026.

The brief profile and other requisite details pertaining to the aforesaid appointment are enclosed as **"Annexure – 1", "Annexure – 2"** and **"Annexure – 3",** respectively.

3) **Resignation of Mr. Narsimha Shibroor Kamath (DIN: 00140593) from the position of Managing Director of the Company and other positions:**

The Board has noted and taken on record the resignation of Mr. Narsimha Shibroor Kamath ("**Mr. Kamath**") from the position of Managing Director of the Company with effect from September 28, 2026.

The resignation letter received from Mr. Kamath is enclosed herewith.

The requisite details as required under Regulation 30 of the SEBI Listing Regulations read with Schedule III thereof SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762 /2026 dated January 30, 2026 attached as **"Annexure – 4"**.

4) **Approval of Postal Ballot Notice:**

Approved the draft Postal Ballot Notice seeking approval of the Members of the Company for the appointment of Mr. Hetul Krishnakant Mehta, Mr. Amar Dilip Shah and Mr. Pramod Badrinarayan Kasat as Non-Executive Non-Independent Directors of the Company. The Postal Ballot Notice will be dispatched to the Members of the Company in accordance with the applicable provisions of the Companies Act, 2013, the rules made thereunder and the SEBI Listing Regulations.

The meeting of the Board of Directors commenced at 6:41 p.m. and concluded at 6:57 p.m.

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.
TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771
Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

Kindly take the above information on your record and acknowledge.

Thanking you,

Yours Faithfully,

For Bliss GVS Pharma Limited

ADITI HIMANSHU BHATT
Digitally signed by ADITI HIMANSHU BHATT
Date: 2026.09.28 20:22:59 +05'30'

Aditi Bhatt
Company Secretary & Compliance Officer

Encl.: As above

"Annexure – 1"

No.	Particulars	Change
1	**Name of the Person**	Mr. Hetul Krishnakant Mehta
2	**Reason for change viz. appointment, ~~reappointment, resignation, removal, death or otherwise~~**	Appointment
3	**Date of appointment / ~~cessation~~ & Term of appointment**	September 28, 2026
4	**Brief Profile**	Mr. Hetul K. Mehta is an entrepreneur with over 30 years of experience in the pharmaceutical industry, particularly in bulk drug manufacturing. He is the Managing Director of Praveen Laboratories Pvt. Ltd., which he co-founded in 1995. He has extensive experience in pharmaceutical manufacturing, regulatory compliance, quality assurance and strategic business management. He has served as an Independent Director of Anupam Rasayan India Limited from 2021 to 2024 and chaired various Board Committees. He is also associated with Globe Envirocare Ltd. and Advanced Diabetes Centre Pvt. Ltd. He has been actively involved with industry bodies including CII and the South Gujarat Chamber of Commerce and Industry. He holds a degree in Chemical Engineering from Bharati Vidyapeeth, Pune.
5	**Disclosure of relationships between directors**	No relation with any of the directors of the Company.
6	**Other Confirmation**	Mr. Hetul Krishnakant Mehta is not debarred or disqualified from being appointed or continuing as a Director of the Company by the SEBI, MCA or any other statutory or regulatory authority order or directions.

"Annexure – 2"

No.	Particulars	Change
1	**Name of the Person**	Mr. Amar Dilip Shah
2	**Reason for change viz. appointment, ~~reappointment, resignation, removal, death or otherwise~~**	Appointment
3	**Date of appointment / ~~cessation~~ & Term of appointment**	September 28, 2026
4	**Brief Profile**	Mr. Amar Dilip Shah is an experienced business professional with extensive experience in sales, marketing, business development and strategic planning. He is currently associated with Siyaram Silk Mills Limited, where he is responsible for sales across Japan, India and USA and also oversees the P&L of a greenfield garment manufacturing unit. He has significant experience in the apparel and textile industry, including working with high street brands and garment converters. He previously served as Working Director of Futuristic Concepts Media Limited for over 22 years. He has also been associated with Web Werks India Pvt. Ltd., where he handled sales, marketing and business operations. He has expertise in establishing new ventures, operational management, technology implementation and business expansion. He has also undertaken programmes in renewable energy, international energy policy and project management.
5	**Disclosure of relationships between directors**	No relation with any of the directors of the Company.
6	**Other Confirmation**	Mr. Amar Dilip Shah is not debarred or disqualified from being appointed or continuing as a Director of the Company by the SEBI, MCA or any other statutory or regulatory authority order or directions.

"Annexure – 3"

No.	Particulars	Change
1	**Name of the Person**	Mr. Pramod Badrinarayan Kasat
2	**Reason for change viz. appointment, ~~reappointment, resignation, removal, death or otherwise~~**	Appointment
3	**Date of appointment / ~~cessation~~ & Term of appointment**	September 28, 2026
4	**Brief Profile**	Mr. Pramod Badrinarayan Kasat is a seasoned Investment Banker with over three decades of experience in structured finance, investment banking and private credit. He is currently the Managing Director of Intellecap, the investment banking arm of the Aavishkaar Group. He has led transactions across healthcare, infrastructure, industrials, logistics and technology-enabled businesses, with cumulative deal experience exceeding USD 5 billion. He has previously held senior positions at IndusInd Bank, Credit Suisse, Deutsche Bank and IL&FS. He has extensive experience as an Independent Director on listed and private companies. He holds an MBA from the University of Mumbai and a Bachelor of Engineering (Hons.) in Electronics from BITS Pilani.
5	**Disclosure of relationships between directors**	No relation with any of the directors of the Company.
6	**Other Confirmation**	Mr. Pramod Badrinarayan Kasat is not debarred or disqualified from being appointed or continuing as a Director of the Company by the SEBI, MCA or any other statutory or regulatory authority order or directions.

"Annexure – 4"

No.	Particulars	Change
1	**Name of the Person**	Mr. Narsimha Shibroor Kamath
2	**Reason for change viz. ~~appointment, reappointment,~~ resignation, ~~removal, death or otherwise~~**	Resignation pursuant to and in connection with completion of the transactions contemplated under the SPA. The reasons for resignation are mentioned in the resignation letter dated September 28, 2026, which is attached herewith.
3	**Date of ~~appointment /~~ cessation ~~& Term of appointment~~**	September 28, 2026
4	**Brief Profile**	Not Applicable
5	**Disclosure of relationships between directors**	No Relation with any other director as on date.

Date: September 28, 2026

To,
The Board of Directors
Bliss GVS Pharma Limited
102, Hyde Park, Saki Vihar Road, Andheri (East),
Mumbai – 400 072, Maharashtra, India

Subject: Resignation from the positions held in Bliss GVS Pharma Limited.

Dear Sir/Madam,

Pursuant to the terms of the share purchase agreement dated May 23, 2026 ("**SPA**"), entered into amongst Anupam Rasayan India Limited ("**Purchaser**"), the Sellers (as defined in the SPA), including myself as Seller 1 (as defined in the SPA), read with the Deed of Adherence dated July 17, 2026, executed between Mates Visa Consultancy Private Limited ("**PAC")** and the Purchaser ("**DOA**"), whereby the Purchaser has assigned its rights under the SPA to the PAC and in connection with the completion of the transactions contemplated under the SPA.

In accordance with the terms of the SPA, I hereby tender my resignation from all positions held by me in connection with Bliss GVS Pharma Limited ("**Company**").

Accordingly, I hereby resign, **with effect from September 28, 2026, upon conclusion of the agenda item relating to my resignation at the meeting of the Board of Directors of the Company held on September 28, 2026**, from the following positions, offices and responsibilities:

1. Managing Director of the Company;

2. Chairmanship, membership or any other position held by me on any committee of the Board of Directors of the Company, whether statutory or non-statutory and whether as Chairman, Member or otherwise; and

3. Any other position, office, authority, responsibility or appointment held by me in the Company by virtue of my association with the Company.

I request the Board of Directors of the Company to take note of and accept my resignation from the aforesaid positions and to record my cessation therefrom **with effect from September 28, 2026, upon conclusion of the aforesaid agenda item** and to undertake all necessary actions, filings, disclosures and other compliances as may be applicable. I hereby authorise the Company to use, file, disclose, publish and/or submit this resignation letter, including the reasons for my resignation stated herein, with the stock exchanges, the Registrar of Companies, the Securities and Exchange Board of India and/or any other statutory, regulatory or governmental authority, as may be required under the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws.

I hereby confirm that I do not hold any position in any of the Subsidiaries (as defined in SPA) of Bliss GVS Pharma Limited.

I confirm that this resignation is being tendered pursuant to and in connection with the completion of the transactions contemplated under the SPA, read with the DOA, and the consequent change in control of the Company, including the transition of management and Board responsibilities of the Company. I further confirm that there are no other material reasons for my resignation other than those stated above.

I take this opportunity to express my sincere appreciation to the Board of Directors, shareholders, employees, customers and other stakeholders of the Company for their support and cooperation during my association with the Company.

Thanking you,

Yours faithfully,

S. N. Kamath

S N Kamath
Managing Director
DIN: 00140593
Add: 102, Hyde Park,
Saki Vihar Road, Andheri (East),
Mumbai – 400 072, Maharashtra, India

28/04/2026

Received

BLISS GVS PHARMA LTD.
MUMBAI